Mass General Brigham unveils new gene therapy institute
Last week, New England Council member, Mass General Brigham, announced a new gene therapy institute, aimed at rethinking the traditional biotech research model and creating a new role for Mass General Brigham.
The Gene and Cell Therapy Institute was launched in December to centralize the work of MGB’s more than 400 gene and cell therapy researchers across its five academic medical centers. The GCTI will not only help MGB doctors balance research and patient care by providing manufacturing and regulatory support, but also allow for more extensive research to be completed within MGB walls, instead of moving to a third-party location or opening another laboratory. Gene and cell therapy practices are becoming increasingly influential in modern medicine practices, the GCTI is predicted to greatly increase employment and technological advancements.
“We’re trying to take the best of the VC world and the best of the academic world and merge it together in a way that is going to differentiate it from other gene therapy institutes and other academic centers,” said Nathan Yozwiak, head of research at the GCTI.
The New England Council commends Mass General Brigham for its commitment to furthering scientific advancements.
Read more from the Boston Business Journal.